Last reviewed · How we verify

EMD Serono Research & Development Institute, Inc. — Portfolio Competitive Intelligence Brief

EMD Serono Research & Development Institute, Inc. pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tecfidera Tecfidera marketed Hydroxycarboxylic acid receptor 2, Kelch-like ECH-associated protein 1 Immunology
Avelumab Weekly Avelumab Weekly phase 3 PD-L1 inhibitor PD-L1 Oncology
Fluorouracil (5-FU) Fluorouracil (5-FU) phase 3 Antimetabolite Thymidylate synthase Oncology
Rebif® new formulation (RNF) Rebif® new formulation (RNF) phase 3 Interferon IFNAR Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hoffmann-La Roche · 2 shared drug classes
  2. Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 2 shared drug classes
  3. Asan Medical Center · 1 shared drug class
  4. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 shared drug class
  7. Bayer · 1 shared drug class
  8. Ascletis Pharmaceuticals Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for EMD Serono Research & Development Institute, Inc.:

Cite this brief

Drug Landscape (2026). EMD Serono Research & Development Institute, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/emd-serono-research-development-institute-inc. Accessed 2026-05-16.

Related